Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0001112

Gestodene

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(17α)-13-Ethyl-17-hydroxy-18,19-Dinorpregna-4,15-dien-20-yn-3-one, Gestinol, SHB 331, WL 70

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C21H26O2
Numéro CAS:
60282-87-3
Poids moléculaire :
310.43
Numéro MDL:
MFCD00867858
Code UNSPSC :
41116107
ID de substance PubChem :
329831269
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

gestodene

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C

InChI

1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

Clé InChI

SIGSPDASOTUPFS-XUDSTZEESA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Gestodene EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Gestodene is a synthetic progestin used as a contraceptive. Gestodene displays a high binding affinity to the progesterone receptor, and also binds strongly to adrogen and glucocorticoid receptors.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Warning

Mentions de danger

H361fd

Conseils de prudence

P201 - P308 + P313

Classification des risques

Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Ladakan Jaithitivit et al.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 95(5), 630-635 (2012-09-22)
To determine cycle control, safety, and acceptability of a 24-day oral contraceptive regimen containing 15 micrograms of ethinylestradiol and 60 micrograms of gestodene. This was an open-label, non-comparative study. Healthy women 18 to 35 years old who attended the Family
Romana Dmitrovic et al.
Obstetrics and gynecology, 119(6), 1143-1150 (2012-05-24)
To estimate whether continuous oral contraceptive pills (OCPs) will result in more pain relief in primary dysmenorrhea patients than cyclic OCPs, which induce withdrawal bleeding with associated pain and symptoms. We conducted a double-blind, randomized, controlled trial comparing continuous to
Sopon Cheewadhanaraks et al.
Gynecologic and obstetric investigation, 74(2), 151-156 (2012-06-23)
To evaluate the efficacy and tolerability of postoperative depot medroxyprogesterone acetate (DMPA) versus postoperative continuous oral contraceptive (OC) pills in the treatment of endometriosis-associated pain. After a conservative surgery, 84 patients with symptomatic endometriosis were randomized to receive either intramuscular
Øjvind Lidegaard et al.
BMJ (Clinical research ed.), 343, d6423-d6423 (2011-10-27)
To assess the risk of venous thromboembolism from use of combined oral contraceptives according to progestogen type and oestrogen dose. National historical registry based cohort study. Four registries in Denmark. Non-pregnant Danish women aged 15-49 with no history of thrombotic
Hormone-based contraceptive therapy and risk of venous thromboembolism in young women.
Helen Roberts
Clinical advances in hematology & oncology : H&O, 8(5), 307-309 (2010-06-17)
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique